DengiAll
Panacea Biotec stock jumps 9%! Key breakthrough in Phase III Dengue vaccine trial sparks rally
Kolkata/IBNS: Shares of Panacea Biotec Ltd. surged around 9 per cent on Thursday after the pharmaceutical and vaccine maker announced the completion of enrollment for the Phase III clinical trial of its dengue vaccine candidate, DengiAll, media reports said.
The company has enrolled a total of 10,335 participants in the late-stage trial, marking a key milestone in the development of India’s indigenous dengue vaccine.
Under the study protocol, each participant will be monitored for a period of two years after receiving either the vaccine or a placebo to assess the efficacy, safety and immunogenicity of the candidate.
DengiAll is a live-attenuated tetravalent dengue vaccine designed to provide protection against all four dengue virus serotypes.
The vaccine development programme began in 2006, using licensed dengue virus strains from the National Institutes of Health (NIH), USA, and has already successfully completed Phase I and Phase II clinical trials in India.
The ongoing Phase III trial is aimed at evaluating the vaccine’s safety, immunogenicity and efficacy in the Indian population, with long-term follow-up of participants forming a crucial part of the study.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
